Key takeaway
In a crossover trial of 26 people with Alzheimer's disease, a 12-week modified ketogenic diet raised daily-function scores (ADCS-ADL +3.13 points, P = 0.0067) and quality-of-life scores (QOL-AD +3.37, P = 0.023) versus usual diet, but not cognition (ACE-III +2.12, P = 0.24). The trial was very small, and the abstract does not report any long-term follow-up.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Brain energy metabolism is impaired in Alzheimer's disease (AD), and ketones from a ketogenic diet might offer the brain another fuel. The authors tested whether a 12-week modified ketogenic diet improves cognition, daily function or quality of life in clinic patients with AD.
Who and how
Single-phase, assessor-blinded, randomized two-period crossover trial in a hospital clinic. Patients with clinically confirmed AD received a modified ketogenic diet or usual diet plus low-fat healthy-eating guidelines, each for 12 weeks, separated by a 10-week washout. Primary outcomes were within-individual changes over 12 weeks in the Addenbrooke's Cognitive Examination III (ACE-III), the AD Cooperative Study Activities of Daily Living (ADCS-ADL) inventory and the Quality of Life in AD (QOL-AD) questionnaire. Secondary outcomes were cardiovascular risk factors and adverse effects. Registered with ANZCTR (ACTRN12618001450202).
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 126 patients were randomized and 21 (81%) completed the ketogenic diet; only one withdrawal was attributed to it. Ketosis was sustained (12-week mean beta-hydroxybutyrate 0.95 ± 0.34 mmol/L).
- 2Daily function (ADCS-ADL) rose by 3.13 ± 5.01 points compared with usual diet (P = 0.0067).
- 3Quality of life (QOL-AD) rose by 3.37 ± 6.86 points (P = 0.023).
- 4Cognition (ACE-III) increased by 2.12 ± 8.70 points, which was not statistically significant (P = 0.24). Cardiovascular risk factors mostly changed favourably and adverse effects were mild.
Limits & uncertainty
- 1With only 26 randomized patients, the estimates are imprecise, as the large standard deviations show.
- 2The diet cannot be hidden from patients or carers, and ADCS-ADL and QOL-AD involve reports that may be influenced by knowing the diet, even though assessors were blinded.
- 3Each diet lasted 12 weeks, so it says nothing about longer-term benefit, safety or whether gains persist after stopping.
- 4This reading is based on the abstract only; the abstract does not report whether carry-over between periods was tested.
What to take from it
The trial shows a ketogenic diet looked feasible and safe in the short term for a small group with AD, with possible gains in daily functioning. It does not show it slows the disease or improves memory. Dietary changes in dementia should be arranged with the person's clinician and dietitian.
Reading your own data
This is clinician-supervised care, not a self-experiment. If a care team uses a diet like this, ketone readings, weight, blood pressure and a daily function log can help them, compared against the person's own earlier baseline.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Brain energy metabolism is impaired in Alzheimer's disease (AD), which may be mitigated by a ketogenic diet. We conducted a randomized crossover trial to determine whether a 12-week modified ketogenic diet improved cognition, daily function, or quality of life in a hospital clinic of AD patients.
Methods
We randomly assigned patients with clinically confirmed diagnoses of AD to a modified ketogenic diet or usual diet supplemented with low-fat healthy-eating guidelines and enrolled them in a single-phase, assessor-blinded, two-period crossover trial (two 12-week treatment periods, separated by a 10-week washout period). Primary outcomes were mean within-individual changes in the Addenbrookes Cognitive Examination - III (ACE-III) scale, AD Cooperative Study - Activities of Daily Living (ADCS-ADL) inventory, and Quality of Life in AD (QOL-AD) questionnaire over 12 weeks. Secondary outcomes considered changes in cardiovascular risk factors and adverse effects.
Results
We randomized 26 patients, of whom 21 (81%) completed the ketogenic diet; only one withdrawal was attributed to the ketogenic diet. While on the ketogenic diet, patients achieved sustained physiological ketosis (12-week mean beta-hydroxybutyrate level: 0.95 ± 0.34 mmol/L). Compared with usual diet, patients on the ketogenic diet increased their mean within-individual ADCS-ADL (+ 3.13 ± 5.01 points, P = 0.0067) and QOL-AD (+ 3.37 ± 6.86 points, P = 0.023) scores; the ACE-III also increased, but not significantly (+ 2.12 ± 8.70 points, P = 0.24). Changes in cardiovascular risk factors were mostly favourable, and adverse effects were mild.
Conclusions
This is the first randomized trial to investigate the impact of a ketogenic diet in patients with uniform diagnoses of AD. High rates of retention, adherence, and safety appear to be achievable in applying a 12-week modified ketogenic diet to AD patients. Compared with a usual diet supplemented with low-fat healthy-eating guidelines, patients on the ketogenic diet improved in daily function and quality of life, two factors of great importance to people living with dementia.
Trial registration
This trial is registered on the Australia New Zealand Clinical Trials Registry, number ACTRN12618001450202 . The trial was registered on August 28, 2018.
Sources & attribution
Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease.
Phillips MCL, Deprez LM, Mortimer GMN, Murtagh DKJ, McCoy S, Mylchreest R, Gilbertson LJ, Clark KM, Simpson PV, McManus EJ, Oh JE, Yadavaraj S, King VM, Pillai A, Romero-Ferrando B, Brinkhuis M, Copeland BM, Samad S, Liao S, Schepel JAC.
Alzheimer's research & therapy · 2021-02-23
DOI: 10.1186/s13195-021-00783-x ↗PubMed · 33622392 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

